Trending...
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
$BEAT Forms Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care. HeartBeam, Inc. (Stock Symbol: BEAT)
SANTA CLARA, Calif. - WisconsinEagle -- Creating First Ever Cable-Free 12-Lead ECG Capable of Capturing Cardiac Electrical Signals from Three Dimensions.
Technology Designed for Portable Devices to Deliver Actionable Heart Intelligence Anywhere.
Clinical Endpoints Successfully Met in Pivotal Study for Groundbreaking 12-Lead ECG Synthesis Technology.
Milestone Study Results Form the Basis of 12-Lead ECG Synthesis Software Application Submitted to FDA in January, 2025.
Strategic Collaboration with AccurKardia Brings Together Two Leaders in Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring.
Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology.
Commenced Early Access Program to Attain Key Insights and Establish Sales Funnel in Preparation for Commercialization.
Submitted 510(k) Application to FDA for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software.
Gross Proceeds of ~$11.5 Million from Public Offering and Over-Allotment Option to Fund Near-Term Milestones.
Awarded Diamond Pinnacle Healthcare Award in Medical Device Innovation.
Cash and Cash Equivalents Totaled $2.4 Million as of December 31, 2024, with Net Cash Used in Operating Activities of $14.5 Million During 2024.
HeartBeam, Inc. (Stock Symbol: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. BEAT is creating the first ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This BEAT platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. BEAT holds 14 US and 4 international issued patents related to technology enablement.
Clinical Endpoints Successfully Met in Pivotal Study for Groundbreaking 12-Lead ECG Synthesis Technology
On April 29th BEAT announced that its groundbreaking synthesized 12-lead electrocardiogram (ECG) successfully met the clinical endpoints in the VALID-ECG pivotal study. Thomas Deering, M.D., of Piedmont Heart Institute, presented the data during the just concluded Heart Rhythm Society's annual conference in San Diego.
The study evaluated the mean difference in ECG intervals and amplitudes between the BEAT HeartBeam synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing non-life-threatening arrhythmias. Data showed a 93.4% overall diagnostic agreement, indicating that BEAT HeartBeam synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs.
More on Wisconsin Eagle
BEAT patented 3D ECG technology captures the heart's electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG using a personalized transformation matrix. Data from the VALID-ECG study formed the basis of the FDA application for the 12-lead ECG synthesis software submitted by HeartBeam in January 2025.
BEAT plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software. In advance of that, BEAT recently commenced an Early Access Program to obtain important feedback on the end-to-end clinical workflow, ensure operational readiness and establish an early adopter funnel in anticipation of US commercialization.
Strategic Collaboration with AccurKardia to Advance Cardiac Monitoring Innovation
On April 24th BEAT announced a strategic collaboration with AccurKardia, an innovator in ECG-based diagnostics technology, bringing together two innovation leaders in ambulatory electrocardiogram (ECG) recording and analysis. The initial collaboration aims to enhance the accessibility of cardiac monitoring solutions and will focus on making AccurKardia's FDA-cleared ECG analysis software, AccurECG™, available on BEAT devices. For more information on AccurKardia visit www.accurkardia.com.
The BEAT groundbreaking credit card-sized, cable-free 3D ECG device captures the heart's electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG using a personalized transformation matrix. BEAT plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software.
Adding AccurKardia's FDA-cleared, device-agnostic automated ECG interpretation platform to the BEAT device will enhance the Company's subsequent commercial offering for arrhythmia assessment by enabling patients and physicians to get an automated rhythm assessment which will facilitate a quicker diagnosis and faster access to clinical care when needed. The strategic collaboration is expected to expedite BEAT product development efforts, reducing both costs and timelines.
"We believe combining AccurKardia's device‑agnostic, FDA‑cleared automated ECG analytics with HeartBeam's novel credit card‑sized device will be a true game‑changer that empowers patients to take charge of their cardiac health, wherever they are. By uniting our strengths, we're creating a best‑in‑class platform that transforms how cardiac arrhythmia conditions are monitored and detected," said Juan C. Jimenez, Co-Founder and Chief Executive Officer of AccurKardia. Putting clinical-grade ECG insights directly into a patient's pocket aims to meaningfully address the increasing lack of access to cardiology specialists in the United States."
More on Wisconsin Eagle
Fourth Quarter and Full Year 2024 Results
On March 13th BEAT reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
BEAT Operational Highlights
FDA 510(k) Clearance & Early Access Program:
Received US Food and Drug Administration (FDA) 510(k) clearance of the BEAT HeartBeam System for comprehensive arrhythmia assessment in December 2024.
Commenced an Early Access Program to obtain important feedback on the end-to-end clinical workflow, ensure operational readiness and establish an early adopter funnel in anticipation of US commercialization.
12-Lead Synthesis Software FDA Submission:
Submitted FDA 510(k) application focused on the BEAT HeartBeam software that converts the heart's electrical signals captured from 3 distinct directions into a synthesized 12-lead ECG, utilizing the company's patented technology.
Plan to present VALID-ECG pivotal study results on 12-lead ECG synthesis software at the Heart Rhythm Society (HRS) meeting in April 2025. This study is the basis of the FDA 510(k) submission.
BEAT anticipates initiating commercialization upon receiving 510(k) clearance for the 12-lead ECG synthesis software.
Other Highlights:
Closed a Public Offering of common stock with gross proceeds of approximately $11.5 million, including the exercise of the underwriter's over-allotment option, to fund key growth milestones and preparation for US commercialization.
Continued to build significant clinical evidence on BEAT HeartBeam technology: At the American Heart Association (AHA) conference in November 2024, presented results from a pilot study demonstrating similar performance between BEAT HeartBeam synthesized 12-lead ECG and a standard 12-lead ECG for arrhythmia detection. The pilot study used the same protocol as the VALID-ECG pivotal study. Also, at AHA, presented data from a feasibility study on a novel algorithm, used in conjunction with the BEAT HeartBeam ECG technology, to detect acute coronary conditions like heart attacks.
BEAT awarded Diamond Pinnacle Healthcare Award in Medical Device Innovation, adding to the growing body of industry recognition in March 2025.
Cash and cash equivalents totaled $2.4 million as of December 31, 2024, with net cash used in operating activities of $14.5 million during 2024.
For more information on $BEAT visit: www.HeartBeam.com
Media Contact:
Company Name: HeartBeam, Inc. (Stock Symbol: BEAT)
Contact: Robert Eno, Chief Executive Officer
Email: media@heartbeam.com
Phone: 408-899-4443
Country: United States
Website: www.HeartBeam.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Technology Designed for Portable Devices to Deliver Actionable Heart Intelligence Anywhere.
Clinical Endpoints Successfully Met in Pivotal Study for Groundbreaking 12-Lead ECG Synthesis Technology.
Milestone Study Results Form the Basis of 12-Lead ECG Synthesis Software Application Submitted to FDA in January, 2025.
Strategic Collaboration with AccurKardia Brings Together Two Leaders in Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring.
Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology.
Commenced Early Access Program to Attain Key Insights and Establish Sales Funnel in Preparation for Commercialization.
Submitted 510(k) Application to FDA for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software.
Gross Proceeds of ~$11.5 Million from Public Offering and Over-Allotment Option to Fund Near-Term Milestones.
Awarded Diamond Pinnacle Healthcare Award in Medical Device Innovation.
Cash and Cash Equivalents Totaled $2.4 Million as of December 31, 2024, with Net Cash Used in Operating Activities of $14.5 Million During 2024.
HeartBeam, Inc. (Stock Symbol: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. BEAT is creating the first ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This BEAT platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. BEAT holds 14 US and 4 international issued patents related to technology enablement.
Clinical Endpoints Successfully Met in Pivotal Study for Groundbreaking 12-Lead ECG Synthesis Technology
On April 29th BEAT announced that its groundbreaking synthesized 12-lead electrocardiogram (ECG) successfully met the clinical endpoints in the VALID-ECG pivotal study. Thomas Deering, M.D., of Piedmont Heart Institute, presented the data during the just concluded Heart Rhythm Society's annual conference in San Diego.
The study evaluated the mean difference in ECG intervals and amplitudes between the BEAT HeartBeam synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing non-life-threatening arrhythmias. Data showed a 93.4% overall diagnostic agreement, indicating that BEAT HeartBeam synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs.
More on Wisconsin Eagle
- Tribeca Film Festival Official Podcast Selection Lead Features Hollywood Stars, Focuses On Ending Childhood Lead Poisoning In New York!
- Industrial Parts Fittings Champions the Revival of American Manufacturing
- Give your guests another option with this roulette machine
- $34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD
- Annemieke van der Werf Joins Brookfield, Wis., Office of Ameriprise Financial
BEAT patented 3D ECG technology captures the heart's electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG using a personalized transformation matrix. Data from the VALID-ECG study formed the basis of the FDA application for the 12-lead ECG synthesis software submitted by HeartBeam in January 2025.
BEAT plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software. In advance of that, BEAT recently commenced an Early Access Program to obtain important feedback on the end-to-end clinical workflow, ensure operational readiness and establish an early adopter funnel in anticipation of US commercialization.
Strategic Collaboration with AccurKardia to Advance Cardiac Monitoring Innovation
On April 24th BEAT announced a strategic collaboration with AccurKardia, an innovator in ECG-based diagnostics technology, bringing together two innovation leaders in ambulatory electrocardiogram (ECG) recording and analysis. The initial collaboration aims to enhance the accessibility of cardiac monitoring solutions and will focus on making AccurKardia's FDA-cleared ECG analysis software, AccurECG™, available on BEAT devices. For more information on AccurKardia visit www.accurkardia.com.
The BEAT groundbreaking credit card-sized, cable-free 3D ECG device captures the heart's electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG using a personalized transformation matrix. BEAT plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software.
Adding AccurKardia's FDA-cleared, device-agnostic automated ECG interpretation platform to the BEAT device will enhance the Company's subsequent commercial offering for arrhythmia assessment by enabling patients and physicians to get an automated rhythm assessment which will facilitate a quicker diagnosis and faster access to clinical care when needed. The strategic collaboration is expected to expedite BEAT product development efforts, reducing both costs and timelines.
"We believe combining AccurKardia's device‑agnostic, FDA‑cleared automated ECG analytics with HeartBeam's novel credit card‑sized device will be a true game‑changer that empowers patients to take charge of their cardiac health, wherever they are. By uniting our strengths, we're creating a best‑in‑class platform that transforms how cardiac arrhythmia conditions are monitored and detected," said Juan C. Jimenez, Co-Founder and Chief Executive Officer of AccurKardia. Putting clinical-grade ECG insights directly into a patient's pocket aims to meaningfully address the increasing lack of access to cardiology specialists in the United States."
More on Wisconsin Eagle
- Pikmykid Launches $100,000 School Safety Grant Giveaway to Support K–12 Schools Across the U.S
- Slotozilla Data Report: Unveiling 2024's Gaming Statistics
- BK Flooring Releases Their Top Reasons to Upgrade Kitchen Tile Flooring in 2025
- The OpenSSL Corporation and the OpenSSL Foundation Certify Results of Technical Advisory Committee Elections
- ROME-ANTICS Unleashed: A Music Video by Sidow Sobrino Transforms Rome into a Living Stage
Fourth Quarter and Full Year 2024 Results
On March 13th BEAT reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
BEAT Operational Highlights
FDA 510(k) Clearance & Early Access Program:
Received US Food and Drug Administration (FDA) 510(k) clearance of the BEAT HeartBeam System for comprehensive arrhythmia assessment in December 2024.
Commenced an Early Access Program to obtain important feedback on the end-to-end clinical workflow, ensure operational readiness and establish an early adopter funnel in anticipation of US commercialization.
12-Lead Synthesis Software FDA Submission:
Submitted FDA 510(k) application focused on the BEAT HeartBeam software that converts the heart's electrical signals captured from 3 distinct directions into a synthesized 12-lead ECG, utilizing the company's patented technology.
Plan to present VALID-ECG pivotal study results on 12-lead ECG synthesis software at the Heart Rhythm Society (HRS) meeting in April 2025. This study is the basis of the FDA 510(k) submission.
BEAT anticipates initiating commercialization upon receiving 510(k) clearance for the 12-lead ECG synthesis software.
Other Highlights:
Closed a Public Offering of common stock with gross proceeds of approximately $11.5 million, including the exercise of the underwriter's over-allotment option, to fund key growth milestones and preparation for US commercialization.
Continued to build significant clinical evidence on BEAT HeartBeam technology: At the American Heart Association (AHA) conference in November 2024, presented results from a pilot study demonstrating similar performance between BEAT HeartBeam synthesized 12-lead ECG and a standard 12-lead ECG for arrhythmia detection. The pilot study used the same protocol as the VALID-ECG pivotal study. Also, at AHA, presented data from a feasibility study on a novel algorithm, used in conjunction with the BEAT HeartBeam ECG technology, to detect acute coronary conditions like heart attacks.
BEAT awarded Diamond Pinnacle Healthcare Award in Medical Device Innovation, adding to the growing body of industry recognition in March 2025.
Cash and cash equivalents totaled $2.4 million as of December 31, 2024, with net cash used in operating activities of $14.5 million during 2024.
For more information on $BEAT visit: www.HeartBeam.com
Media Contact:
Company Name: HeartBeam, Inc. (Stock Symbol: BEAT)
Contact: Robert Eno, Chief Executive Officer
Email: media@heartbeam.com
Phone: 408-899-4443
Country: United States
Website: www.HeartBeam.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on Wisconsin Eagle
- PBK Miner completes $80 million Series B financing to support AI cloud mining and increase user investment return by 25%
- Asset-Backed Green Crypto: Fueling the Trillion-Dollar Revolution
- Two Waukesha Organizations Join Forces for a Unique Choral Concert Experience
- Fairmint Introduces First Fully Onchain and Open Cap Table Infrastructure
- Vortex Brands Begins Gold Purchases Under New Joint Venture with Dubai-Based Partner
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- When The Call Hits Home Podcast Features Tom Rizzo
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories